These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35860251)

  • 1. The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers.
    Hensler E; Petros H; Gray CC; Chung CS; Ayala A; Fallon EA
    Front Immunol; 2022; 13():940930. PubMed ID: 35860251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role and application of programmed death protein 1 (PD-1) and its ligand PD-L1 in immune cell dysfunction in sepsis: An update].
    Ding Y; Dai L; Xiang Y; Sun Y; Yu J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Sep; 36(9):843-848. PubMed ID: 32967768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology.
    Fallon EA; Chung CS; Heffernan DS; Chen Y; De Paepe ME; Ayala A
    Front Immunol; 2021; 12():634529. PubMed ID: 33746973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway.
    Nakamori Y; Park EJ; Shimaoka M
    Front Immunol; 2020; 11():624279. PubMed ID: 33679715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis.
    Huang X; Chen Y; Chung CS; Yuan Z; Monaghan SF; Wang F; Ayala A
    J Immunol; 2014 Feb; 192(3):1091-9. PubMed ID: 24379123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review.
    Sari MI; Ilyas S
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 signaling pathway in sepsis: Does it have a future?
    Chen R; Zhou L
    Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of regulation of PD-1 and PD-L1 expression in sepsis.
    Zhang T; Yu-Jing L; Ma T
    Front Immunol; 2023; 14():1029438. PubMed ID: 36969168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates.
    Young WA; Fallon EA; Heffernan DS; Efron PA; Cioffi WG; Ayala A
    Surgery; 2017 May; 161(5):1387-1393. PubMed ID: 28012568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
    Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
    Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.
    Szereday L; Meggyes M; Berki T; Miseta A; Farkas N; Gervain J; Par A; Par G
    Clin Exp Med; 2020 May; 20(2):219-230. PubMed ID: 32108916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis.
    Avendaño-Ortiz J; Maroun-Eid C; Martín-Quirós A; Lozano-Rodríguez R; Llanos-González E; Toledano V; Gómez-Campelo P; Montalbán-Hernández K; Carballo-Cardona C; Aguirre LA; López-Collazo E
    Front Immunol; 2018; 9():2008. PubMed ID: 30233593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.
    Fallon EA; Biron-Girard BM; Chung CS; Lomas-Neira J; Heffernan DS; Monaghan SF; Ayala A
    J Leukoc Biol; 2018 Feb; ():. PubMed ID: 29393983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.